Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3058 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-08-30

Study Completion Date

2021-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antibiotic-resistant Bacterial Infection of Hepatic Patients

NCT03855709

Antibiotic Resistant Infection Liver Cirrhoses

UNKNOWN

Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

NCT05833282

Drug Resistance, Multiple, Bacterial

UNKNOWN

Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit

NCT04528043

Critically Ill Enterobacteriaceae Infections Antibiotic Resistant Infection

COMPLETED

Clinical Trial to Reduce Antibiotic Resistance in European Intensive Cares

NCT00976638

Hospital Acquired Infections

COMPLETED NA

Bloodstream Infection Due to Multidrug-Resistant Organisms - Multicenter Study on Determinants of Clinical Outcomes

NCT03578835

Bloodstream Infection Septic Shock

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eurobact II is a multinational multicentre cohort study that will include patients with hospital-acquired blood stream infections (HA-BSI) treated in ICUs around the globe. It will provide with an update of the epidemiology of HA-BSI since the Eurobact I study. It is designed to investigate the effects of HA-BSI on mortality at day 28. To describe the determinants of outcomes of HA-BSI, specifically the effects of the source of infection, the microorganism, the characteristics of antimicrobial therapy and of source control. It will investigate patient specific and organizational factors and will describe the determinants of management of HA-BSI in ICUs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bacteremia Sepsis Hospital Acquired Condition Resistance Bacterial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HA-BSI

Patients with HA-BSI treated in an ICU

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 Years.
* Hospital Acquired Bloodstream Infection (HA-BSI).
* Treated in the ICU.

* ICU acquired OR
* Hospital acquired prior to ICU admission

Exclusion Criteria

* Patients that had a positive blood culture in the hospital and transferred to ICU for a different reason than specific treatment of the causes or consequences of HA-BSI.
* Previous inclusion in the study.

* HA-BSI is defined as a positive blood culture (BC) sampled after 48 hours following hospital admission.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No